crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkotikai kaulų ligų gydymui - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
cabemet
sandoz d.d. - kalcipotriolis/betametazonas - tepalas - 50 µg/0,5 mg/g - calcipotriol, combinations
colecalciferol olidetrim
zakłady farmaceutyczne polpharma s.a. - kolekalciferolis - minkštosios kapsulės - 20000 tv - colecalciferol
colecalciferol olidetrim
zakłady farmaceutyczne polpharma s.a. - kolekalciferolis - minkštosios kapsulės - 50000 tv - colecalciferol
colecalciferol krka
krka, d.d., novo mesto - kolekalciferolis - tabletės - 500 tv - colecalciferol
colecalciferol krka
krka, d.d., novo mesto - kolekalciferolis - tabletės - 1000 tv - colecalciferol
enstilar
leo pharma a/s - kalcipotriolis/betametazonas - odos putos - 50 µg/0,5 mg/g - calcipotriol, combinations
xamiol
leo pharma a/s - kalcipotriolis/betametazonas - gelis - 50 µg/0,5 mg/g - calcipotriol, combinations
daivobet
leo pharma a/s - kalcipotriolis/betametazonas - tepalas - 50 µg/0,5 mg/g - calcipotriol, combinations
daivobet
lex ano, uab - kalcipotriolis/betametazonas - tepalas - 50 µg/0,5 mg/g - calcipotriol, combinations